OSLO, Norway, Nov. 21, 2019 /PRNewswire/ --
Oslo, Norway, 21 November 2019
FINANCIAL YEAR 2019
27.02.2020 - Quarterly Report -
Q4
FINANCIAL YEAR 2020
17.04.2020 - Annual General
Meeting
26.05.2020 - Quarterly Report -
Q1
27.08.2020 - Half-yearly Report -
Q2
19.11.2020 - Quarterly Report -
Q3
The dates are subject to change. The time and location of the
presentations will be announced in due time.
This information is published pursuant to the requirements set
out in the Continuing obligations.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting radioimmunotherapy
designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
NHL is an indication with substantial unmet medical need,
representing a growing market forecast to be worth nearly
USD 29 billion by 2026. Nordic
Nanovector intends to retain marketing rights and to actively
participate in the commercialisation of Betalutin® in
core markets.
Further information can be found at
www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant
to the Securities Trading Act, Sections 4-2 and 5-12 / Oslo Stock
Exchange's Continuing Obligations, Section 3.2.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---financial-calendar,c2970226